40137-11-9

Usage

Uses

Used in Pharmaceutical Industry:
Diethyl(methylsulfonylmethyl)phosphonate is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving existing ones.
Used in Agrochemical Industry:
In the agrochemical industry, Diethyl(methylsulfonylmethyl)phosphonate is utilized as an intermediate in the production of herbicides and insecticides, helping to create more effective and targeted pest control solutions.
Used in Research and Development:
Diethyl(methylsulfonylmethyl)phosphonate is employed as a substrate in the study of enzymes and other biological processes, aiding researchers in understanding and advancing the fields of biochemistry and molecular biology.

InChI:InChI=1/C6H15O5PS/c1-4-10-12(7,11-5-2)6-13(3,8)9/h4-6H2,1-3H3

Upstream product

• 14467-94-8 diethyl <(trimethylsilyl)methyl>phosphonate 
• 28460-01-7 diethyl 1-(methylthio)methylphosphonate 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 87762-57-0 (Methylthio)(trimethylsilyl)methylphosphonsaeure-diethylester 
• 122422-71-3 (Methanesulfonyl-trimethylsilanyl-methyl)-phosphonic acid diethyl ester 
• 3167-63-3 diethyl chloromethylphosphonate 
• 73778-52-6 (Methylsulfanyl-phenylsulfanyl-methyl)-phosphonic acid diethyl ester 
• 62999-70-6 S,S-dimethylthioacetal of diethyl oxomethanephosphonate 

Downstream Products

• 35378-31-5 methylcyclohexylidene sulfone 
• 56069-43-3 (E)-1-(2-methanesulfonyl-vinyl)-4-methoxy-benzene 
• 74267-50-8 1-Methanesulfonylmethylene-4-methyl-cyclohexane 
• 894853-81-7 (2-{(1S,5S)-5-(4-Chloro-benzenesulfonyl)-5-(2,5-difluoro-phenyl)-2-[1-methanesulfonyl-meth-(E)-ylidene]-cyclohexylmethoxy}-ethyl)-trimethyl-silane 
• 130948-74-2 (1-Methanesulfonyl-cyclohexyl)-phosphonic acid diethyl ester 
• 99281-93-3 (3S,E)-3-(tert-butoxycarbonylamino)-4-phenyl-1-methylsulfonyl-1-butene 
• 1620107-78-9 (S,E)-tert-butyl (1-cyclohexyl-4-(methylsulfonyl)but-3-en-2-yl)carbamate 
• 1418002-87-5 tert-butyl {trans-4-[2-(methylsulfonyl)vinyl]cyclohexyl}carbamate 
• 1418002-88-6 C₁₄H₂₅NO₄S 
• 1559022-71-7 (3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-methyl-1-((E)-1-(methylsulfonyl)pent-1-en-3-yl)piperidin-2-one 

Relevant academic research and scientific papers

XPO1 protein inhibitors

The invention discloses an XPO1 (Exportin 1) inhibitor of which the structural formula F is as shown in the specification. The XPO1 inhibitor has very good solubility in water; by taking sulforaphene as a representative, the compounds have extremely high inhibitory activity to XPO1, tiny side effect, and good biosafety and bioavailability, and are very suitable for clinical application, so that the XPO1 inhibitor has a huge potential market space and economic benefits.

Selective caspase inhibitors and uses thereof

The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

Design, synthesis, and characterization of α-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase

A series of α-ketooxazoles incorporating electrophiles at the C5 position of the pyridyl ring of 2 (OL-135) and related compounds were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH) that additionally target the cytosolic port Cys269. From this series, a subset of the candidate inhibitors exhibited time-dependent FAAH inhibition and noncompetitive irreversible inactivation of the enzyme, consistent with the targeted Cys269 covalent alkylation or addition, and maintained or enhanced the intrinsic selectivity for FAAH versus other serine hydrolases. A preliminary in vivo assessment demonstrates that these inhibitors raise endogenous brain levels of anandamide and other FAAH substrates upon intraperitoneal (i.p.) administration to mice, with peak levels achieved within 1.5-3 h, and that the elevations of the signaling lipids were maintained >6 h, indicating that the inhibitors effectively reach and remain active in the brain, inhibiting FAAH for a sustained period.

ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.

QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

New aldehyde and vinylsulfone proteasome inhibitors for targeted melanoma therapy

The proteasome is a promising target in cancer therapy. However, it is ubiquitous and its inhibitors cause side effects. To target melanoma cells we synthesized new peptide aldehyde and vinylsulfone inhibitors of the proteasome conjugated to the melanin-targeting ligand (MTL) derived from radiotracer [ 123I]-N-(2-diethylaminoethyl)benzamide ([123I]BZA) or [125I]-N-(4-dipropylaminobutyl)-4-iodobenzamide ([ 125I]BZ18). Influence on the cytotoxicity of the benzamide alkyl side chain length and the composition of the amino acid sequence was assessed. Among the conjugates evaluated, compound 16 and 22 presented the highest cytotoxicity (IC50, 0.71 and 0.64 μM respectively), which persisted in the presence of an MTL derived from N-(dialkylaminoalkylenyl)benzamide residue.

JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. (I).

Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: Design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition

A series of artemisinin-vinyl sulfone hybrid molecules with the potential to act in the parasite food vacuole via endoperoxide activation and falcipain inhibition was synthesized and screened for antiplasmodial activity and falcipain-2 inhibition. All conjugates were active against the Plasmodium falciparum W2 strain in the low nanomolar range and those containing the Leu-hPhe core inhibited falcipain-2 in low micromolar range.

DISPIRO TETRAOXANE COMPOUNDS

A compound having the formula (I) wherein ring A represents a substituted or unsubstituted monocyclic or multicyclic ring; m=any positive integer; n=0-5; X=CH and Y=-C(O)NR1R2, -NR1R2 or -S(O)2R4, where R1, R2 and R4 are each individually selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring, or any combination thereof, or R1 and R2 are linked so as to form part of a substituted or unsubstituted heterocyclic ring, or X=N and Y=-S(O)2R3 or -C(O)R3, where R3 is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring or any combination thereof.